Comprehensive clinical profiling of the Gauting locoregional lung adenocarcinoma donors

• Verfasst von: Klotz, Laura Valentina [VerfasserIn]
• Verfasst von: Eichhorn, Martin E. [VerfasserIn]
• Titel: Comprehensive clinical profiling of the Gauting locoregional lung adenocarcinoma donors
• Verf.angabe: Laura V. Klotz, Yves Courty, Michael Lindner, Agnès Petit‐Courty, Anja Stowasser, Ina Koch, Martin E. Eichhorn, Ioannis Lilis, Alicia Morresi‐Hauf, Kristina A. M. Arendt, Mario Pepe, Ioanna Giopanou, Giannoula Ntaliarda, Sabine J. Behrend, Maria Oplopoiou, Valérie Gissot, Serge Guyetant, Sylvain Marchand‐Adam, Jürgen Behr, Jan-Christian Kaiser, Rudolf A. Hatz, Anne-Sophie Lamort, Georgios T. Stathopoulos
• E-Jahr: 2019
• Jahr: 27 January 2019
• Umfang: 14 S.
• Fussnoten: Gesehen am 08.11.2019
• Titel Quelle: Enthalten in: Cancer medicine
• Ort Quelle: Hoboken, NJ : Wiley, 2012
• Jahr Quelle: 2019
• Band/Heft Quelle: 8(2019), 4, Seite 1486-1499
• ISSN Quelle: 2045-7634
• DOI: doi:10.1002/cam4.2031
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: LADC
• Sach-SW: lung adenocarcinoma
• Sach-SW: obstruction
• Sach-SW: smoking
• Sach-SW: survival
• K10plus-PPN: 1681523167

Abstract

A comprehensive characterization of lung adenocarcinoma (LADC) clinical features is currently missing. We prospectively evaluated Caucasian patients with early-stage LADC. Patients with LADC diagnosed between 2011 and 2015 were prospectively assessed for lung resection with curative intent. Fifty clinical, pathologic, radiologic, and molecular variables were recorded. Patients were followed till death/study conclusion. The main findings were compared to a separate cohort from France. Of 1943 patients evaluated, 366 were enrolled (18.8%; 181 female; 75 never-smokers; 28% of registered Bavarian cases over the study period). Smoking and obstruction were significantly more prevalent in GLAD compared with adult Bavarians (P < 0.0001). Ever-smoker tumors were preferentially localized to the upper lobes. We observed 120 relapses and 74 deaths over 704 cumulative follow-up years. Median overall and disease-free survival were >7.5 and 3.6 years, respectively. Patients aged <45 or >65 years, resected >60 days postdiagnosis, with abnormal FVC/DLCOVA, N2/N3 stage, or solid histology had significantly decreased survival estimates. These were fit into a weighted locoregional LADC death risk score that outperformed pTNM7 in predicting survival in the GLAD and in our second cohort. We define the clinical gestalt of locoregional LADC and provide a new clinical tool to predict survival, findings that may aid future management and research design.